- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.04. | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis | 166 | ACCESS Newswire | HAMILTON, BM / ACCESS Newswire / April 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and commercializing RNA delivery technology... ► Artikel lesen | |
| 31.03. | Altamira Therapeutics GAAP EPS of -$0.55 | 2 | Seeking Alpha | ||
| 31.03. | Altamira Therapeutics Ltd.: Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results | 223 | ACCESS Newswire | Expanding nucleic acid delivery business with new applicationsOngoing optimization of cost structureAdvancing plans for spin-off of nucleic acid delivery business and continuing strategic repositioning... ► Artikel lesen | |
| 24.03. | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements | 198 | ACCESS Newswire | HAMILTON, BM / ACCESS Newswire / March 24, 2026 / Altamira Therapeutics ("Altamira" or the "Company") (OTCID:CYTOF) today announced that it will release its annual report and financial statements for... ► Artikel lesen | |
| ALTAMIRA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.02. | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray | 453 | ACCESS Newswire | HAMILTON, BM / ACCESS Newswire / February 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and supplying nucleic acid delivery technology... ► Artikel lesen | |
| 23.01. | Altamira Therapeutics Ltd.: Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit | 579 | ACCESS Newswire | HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and commercializing nucleic acid delivery... ► Artikel lesen | |
| 19.12.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China | 442 | ACCESS Newswire | Regulatory clearance of Bentrio in allergic rhinitis for Mainland ChinaNearly 200 million Chinese estimated to suffer from allergic rhinitisBentrio to be launched by partner Nuance Pharma HAMILTON,... ► Artikel lesen | |
| 20.11.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation | 728 | ACCESS Newswire | Conformity with stringent new EU regulations for medical devices confirmedAllows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countriesMajor... ► Artikel lesen | |
| 03.11.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules | 340 | ACCESS Newswire | Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and growing... ► Artikel lesen | |
| 29.08.25 | Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results | 767 | ACCESS Newswire | Company to host webcast today at 8.00 a.m. ETGrowing portfolio of RNA delivery clients and programsAdvancing plans for partial spin-off of RNA delivery activitiesContinued adjustment of cost structure... ► Artikel lesen | |
| 26.08.25 | Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025 | 424 | ACCESS Newswire | HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology... ► Artikel lesen | |
| 15.07.25 | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine | 296 | ACCESS Newswire | HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet medical... ► Artikel lesen | |
| 11.06.25 | Delisting of Securities of Blue Star Foods Corp.; Altamira Therapeutics Ltd.; Evergreen Corporation; Fresh2 Group Limited; Coliseum Acquisition Corp.; The Real Good Food Company, Inc.; Mynaric AG; byNordic Acquisition Corporation; ... | 991 | GlobeNewswire (Europe) | NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Blue Star Foods Corp. Blue Star Foods Corp.'s stock was suspended on December... ► Artikel lesen | |
| 30.04.25 | Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results | 527 | GlobeNewswire (Europe) | Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDTRNA delivery business progressing with platform development, new applications... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| EVOTEC | 5,350 | -0,93 % | SCHOCKMELDUNG bei Evotec: Was die wenigsten Anleger auf dem Schirm haben - Meine Strategie für die kommende Handelswoche | ||
| BB BIOTECH | 48,550 | +0,21 % | Umbau bei BB Biotech zahlt sich aus: Aktie schlägt Index trotz Gegenwind | BB Biotech startet solide ins Jahr 2026: Outperformance beim Aktienkurs, aktiver Portfolio-Umbau und mehr Diversifikation. Die Beteiligungsgesellschaft BB Biotech hat im 1. Quartal ein insgesamt solides... ► Artikel lesen | |
| MEDIGENE | 0,020 | -20,47 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| MODERNA | 43,480 | +0,49 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| PAION | 0,047 | -26,77 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,326 | -0,60 % | Was bei Valneva gerade passiert: Warum Sie jetzt genau hinschauen sollten - Was sich am Wochenende verändert hat! | ||
| AMGEN | 295,40 | +0,44 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| EPIGENOMICS | 0,930 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| BIOGEN | 156,62 | -0,43 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| BIOFRONTERA | 2,520 | -0,79 % | Biofrontera: 2025 war ein richtungsweisendes Jahr | Leverkusen (www.anleihencheck.de) - Biofrontera: 2025 war ein richtungsweisendes Jahr - AnleihenewsAnbei eine aktuelle Pressemitteilung der Biofrontera AG (ISIN DE000A4BGGM7/ WKN A4BGGM)- Im dritten... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,740 | +1,86 % | HEIDELBERG PHARMA AG - Ruhe vor dem nächsten Impuls | ||
| ILLUMINA | 109,30 | +0,15 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen |
ALTAMIRA THERAPEUTICS LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALTAMIRA THERAPEUTICS LTD finden Sie auf Wallstreet Online.